Progyny, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-62.5% vs price
Base Case (Median)
-53.5% vs price
Bull Case (75th pct.)
41.4% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $3.85 | -84.8% | High (40%) |
| PE Comparable | $20.47 | -19.2% | Medium (25%) |
| Growth Trajectory DCF | $56.53 | 123.2% | Medium (20%) |
| Graham Number | $11.20 | -55.8% | Medium (40%) |
| EV/EBITDA | $11.78 | -53.5% | Medium (20%) |
| EV/FCF | $51.15 | 101.9% | Medium (20%) |
| Earnings Power Value | $7.80 | -69.2% | Medium (50%) |
Based on 7 out of 8 methods, PGNY appears fairly valued at the current price of $25.33. The base case fair value of $11.78 implies 53.5% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.